Home Biosimilar Antibodies Others Others Romosozumab(anti-sclerostin)
For research use only. Not for use in humans.

Romosozumab(anti-sclerostin)

Synonyms: SOST， sclerostin

Romosozumab is a monoclonal antibody that binds to sclerostin (an inhibitor of the Wingless-related integration site (Wnt) signaling pathway). It is a new osteoanabolic drug, that simultaneously increases bone formation and decreases bone resorption.

Romosozumab(anti-sclerostin)

Quality Control

Batch: Purity: 99% Protein concentration: 7.92mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Romosozumab is a monoclonal antibody that binds to sclerostin (an inhibitor of the Wingless-related integration site (Wnt) signaling pathway). It is a new osteoanabolic drug, that simultaneously increases bone formation and decreases bone resorption.
References

Product Details

CAS No. 909395-70-6
Molecular Weight 150 kDa
Isotype human IGg2, κ
Application Romosozumab(anti-sclerostin)
Purification Protein G
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20 mM Arg, pH 5.0
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06059222 RECRUITING Drug: Romosozumab|Drug: Zoledronate|Drug: Romosozumab|Drug: Osteoporosis University of Aarhus 2023-10-02 PHASE4
NCT07772609 NOT_YET_RECRUITING Drug: Romosozumab|Drug: Zoledronic Acid 5 MG in 5 ML Injecti Osteoporosis in Post-menopausal Women Sahlgrenska University Hospital 2027-01-11 PHASE4
NCT07616401 RECRUITING Osteoporosis; Menopause Istituto Auxologico Italiano 2025-08-31
NCT06938152 RECRUITING Drug: Romosozumab followed by Denosumab|Drug: Romosozumab an Osteoporosis; Osteoporosis Postmenopausal National Taiwan University Hospital 2025-04-08 PHASE4
NCT06533865 RECRUITING Drug: Romosozumab|Drug: Placebo|Drug: Zoledronic acid FHA (Functional Hypothalamic Amenorrhea) Massachusetts General Hospital 2025-03-19 PHASE3
NCT07776613 RECRUITING Drug: Romosozumab Breast Cancer; Metastatic Breast Cancer (MBC) Memorial Sloan Kettering Cancer Center 2026-08-17 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-02)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.